Fig. 4

Targeting dysregulated tumor–stromal signaling in MDA-MB-231 VMT and HCC1599 VMT improves therapeutic responses. A Bar plot showing relative fold change compared to control for different vascular morphometry measurements of MDA-MB-231 TNBC-associated vessel response to razuprotafib 10 nM and 100 nM dose administered in the VMT on day 5 of culture for 48 h. B Fold change in average vessel length in MDA-MB-231 VMT over the course of 6 days post-treatment with 10 nM razuprotafib. C Fold change in vessel lacunarity in MDA-MB-231 VMT over the course of 6 days post-treatment with 10 nM razuprotafib. D Fold change in vessel percent area in MDA-MB-231 VMT over the course of 6 days post-treatment with 10 nM razuprotafib. E Fold change in vascular perfusion with 70 kDa fluorescent dextran in MDA-MB-231 VMT 24 h post-treatment with 10 nM razuprotafib. F Fluorescent micrographs showing MDA-MB-231 VMT with and without razuprotafib 10 nM, with tumors in green and vessels in red. VMT are perfused on day 6 with 70 kDa fluorescent dextran (shown in cyan). G Fold change in average vessel length, H vessel percent area, I vessel lacunarity and (J) tumor growth in treated MDA-MB-231 VMT. K Fluorescent micrographs showing control, L paclitaxel-treated, M razuprotafib-treated, N and combination treated MDA-MB-231 VMT as overlay and vessel only images. O Fold change in tumor growth in treated HCC1599 VMT. P Fluorescent micrographs showing control, Q sapitinib-treated, R MK2206-treated, and S combination treated HCC1599 VMT. Note that stromal cells are present in the VMT but are not fluorescently labeled. *\(p< 0.05\), **\(p < 0.01\), ***\(p < 0.001\)